|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2005
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE05
|
|
gptkbp:bioavailability
|
39% to 49%
|
|
gptkbp:brand
|
gptkb:Nexavar
|
|
gptkbp:casnumber
|
284461-73-0
|
|
gptkbp:chemical_formula
|
C21 H16 Cl F4 N3 O3 S
|
|
gptkbp:clinical_trial
|
Phase III
improved overall response rate in thyroid cancer
improved overall survival in liver cancer
improved progression-free survival in kidney cancer
|
|
gptkbp:clinical_use
|
off-label use for other cancers
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to sorafenib
|
|
gptkbp:developed_by
|
gptkb:Bayer_AG
|
|
gptkbp:dosage_form
|
gptkb:tablet
400 mg twice daily
|
|
gptkbp:duration
|
until disease progression or unacceptable toxicity
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sorafenib
|
|
gptkbp:interacts_with
|
gptkb:simvastatin
gptkb:omeprazole
gptkb:carbamazepine
gptkb:rifampin
gptkb:warfarin
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:lifespan
|
25 to 48 hours
|
|
gptkbp:marketed_as
|
gptkb:Bayer_AG
|
|
gptkbp:mechanism_of_action
|
inhibits multiple kinases
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:related_products
|
gptkb:sunitinib
gptkb:regorafenib
vandetanib
cabozantinib
lenvatinib
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:service_frequency
|
twice daily
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
diarrhea
rash
|
|
gptkbp:storage
|
store at room temperature
keep away from moisture
|
|
gptkbp:used_for
|
treatment of thyroid cancer
treatment of kidney cancer
treatment of liver cancer
|
|
gptkbp:bfsParent
|
gptkb:VEGFR
gptkb:Nexavar
gptkb:Stivarga
|
|
gptkbp:bfsLayer
|
7
|